Bristol-Myers trades at a significant valuation discount, but its higher leverage and patent risks contrast sharply with ...

Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff and $43 billion in debt put ...

Bristol Myers Squibb is executing a visible portfolio transition, with its Growth Portfolio now surpassing Legacy Portfolio.

Earlier this week, Bristol Myers Squibb reported positive Phase 3 results for three key programs: RYZ101 in advanced ...

Over the last year, Bristol-Myers Squibb Company (NYSE:BMY) has done better than the overall market, with its shares ...